<SEC-DOCUMENT>0001140361-22-020274.txt : 20220523
<SEC-HEADER>0001140361-22-020274.hdr.sgml : 20220523
<ACCEPTANCE-DATETIME>20220523165851
ACCESSION NUMBER:		0001140361-22-020274
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220519
FILED AS OF DATE:		20220523
DATE AS OF CHANGE:		20220523

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sooch Mina
		CENTRAL INDEX KEY:			0001674006

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34079
		FILM NUMBER:		22952538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocuphire Pharma, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-05-19</periodOfReport>

    <issuer>
        <issuerCik>0001228627</issuerCik>
        <issuerName>Ocuphire Pharma, Inc.</issuerName>
        <issuerTradingSymbol>OCUP</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001674006</rptOwnerCik>
            <rptOwnerName>Sooch Mina</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O OCUPHIRE PHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>37000 GRAND RIVER AVE, SUITE 120</rptOwnerStreet2>
            <rptOwnerCity>FARMINGTON HILLS</rptOwnerCity>
            <rptOwnerState>MI</rptOwnerState>
            <rptOwnerZipCode>48335</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <officerTitle>President and CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-05-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>12500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.0703</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>412522</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-05-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>12500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.024</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>425022</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The price represents the weighted average price of the multiple transactions reported on this line.  The shares were purchased at prices ranging from $2.045 to $2.10.  Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.</footnote>
        <footnote id="F2">The price represents the weighted average price of the multiple transactions reported on this line.  The shares were purchased at prices ranging from $2.015 to $2.025.  Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Emily J. Johns, by Power of Attorney</signatureName>
        <signatureDate>2022-05-23</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
